Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966250 | 0.96 | ADORA2A (0.92) | ADORA2AADORA1 | |
| SCHEMBL4531259 | 0.95 | ADORA2A (0.91) | ADORA2AADORA1 | |
| SCHEMBL4522764 | 0.95 | ADORA2A (0.90) | ADORA2AADORA1 | |
| SCHEMBL4522722 | 0.93 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL4514581 | 0.92 | ADORA2A (0.85) | ADORA2AADORA1 | |
| SCHEMBL4519764 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL13966151 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL13966138 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL4523284 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL4505905 | 0.91 | ADORA2A (0.83) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | ADORA2A, P2RX6, P2RX5 | ADORA2A 1/4885ADORA1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.